Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03728361

Recruitment Status : Active, not recruiting

First Posted : November 2, 2018

Last Update Posted : April 29, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Bristol-Myers Squibb

Information provided by (Responsible Party):

Dwight Owen, Ohio State University Comprehensive Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	December 31, 2022
Estimated Study Completion Date :	December 31, 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Owen DH, Benner B, Pilcher C, Good L, Savardekar H, Norman R, Ghattas C, Shah M, Konda B, Verschraegen CF, Wesolowski R, Behbehani GK, Carson WE, Otterson GA. Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. Clin Lung Cancer. 2021 Jul;22(4):e487-e497. doi: 10.1016/j.cllc.2020.10.018. Epub 2020 Nov 2.

To Top